saralasin acetate - Profile

What are the generic drug sources for saralasin acetate and what is the scope of freedom to operate?

Saralasin acetate is the generic ingredient in one branded drug marketed by Procter And Gamble and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for saralasin acetate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for saralasin acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Procter And Gamble	SARENIN	saralasin acetate	INJECTABLE;INJECTION	018009-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for saralasin acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Procter And Gamble	SARENIN	saralasin acetate	INJECTABLE;INJECTION	018009-001	Approved Prior to Jan 1, 1982	3,886,134
Procter And Gamble	SARENIN	saralasin acetate	INJECTABLE;INJECTION	018009-001	Approved Prior to Jan 1, 1982	3,932,624

Summary
Saralasin acetate is a peptide antagonist targeting the angiotensin II receptor, developed primarily for hypertension and cardiovascular conditions. Its development has faced challenges related to its peptide nature, delivery, and limited therapeutic efficacy. The drug's current status suggests minimal commercial prospects without significant reformulation or new delivery methods. Investment potential hinges on future innovations or partnerships that overcome these limitations.

---

What is Saralasin Acetate?
Saralasin acetate is a synthetic peptide that antagonizes angiotensin II receptors, mainly used in experimental settings to study the renin-angiotensin system (RAS). It mimics angiotensin II but blocks its effects, which reduces blood pressure. Originally developed in the 1980s, it is a partial agonist/antagonist with high specificity for angiotensin II type 1 receptors (AT1).

Pharmacology and Mechanism of Action
Saralasin binds to AT1 receptors, preventing angiotensin II from exerting vasoconstrictive and aldosterone-secreting effects. Its peptide structure results in rapid degradation and poor oral bioavailability, requiring parenteral administration.

---

Development & Clinical Status

• Initial research targeted hypertension and heart failure.
• Conducted pilot and phase I/II trials in the 1980s and 1990s.
• Limited progression toward regulatory approval due to safety, efficacy, and pharmacokinetic issues.
• Currently, no approved indications or commercial formulations exist.

Key Technical Barriers

• Peptide instability.
• Poor oral absorption.
• Short half-life necessitating continuous infusion or frequent injections.
• Limited therapeutic window and moderate efficacy compared to existing options like ACE inhibitors or ARBs.

---

Market and Competitive Landscape

• Hypertension drugs constitute a mature market with dominant classes: ACE inhibitors, ARBs, calcium channel blockers, and diuretics.
• Saralasin’s non-oral delivery and modest efficacy compare unfavorably.
• No recent regulatory filings or marketed products.
• Growing focus on oral agents with better pharmacokinetics has rendered peptide antagonists less attractive.

Key Competitors

• Losartan, valsartan (ARBs) with proven oral efficacy.
• Captopril, enalapril (ACE inhibitors).
• Newer agents with improved bioavailability and safety profiles.

---

Investment Fundamentals and R&D Outlook

• The peptide nature limits commercial viability unless alternative delivery methods (e.g., nanoparticle encapsulation) are developed.
• Biotech companies or academic labs exploring peptide stability or innovative delivery could repurpose saralasin.
• No recent patents or licensing agreements suggest limited commercial momentum.
• The drug’s future depends on breakthroughs in peptide engineering, or niche applications in research or diagnostics rather than mainstream therapy.

Intellectual Property and Patent Landscape

• Limited patent activity since initial development.
• Existing patents potentially expired or close to expiration.
• No active patent applications for new formulations or indications.

Potential for Repurposing

• Exploratory use in diagnostic assays related to RAS.
• Research tool for studying angiotensin II pathways.
• Limited prospects for therapeutic repositioning without significant reformulation.

---

Financial Considerations

• Minimal R&D investment returns projected given historical stagnation.
• Development costs for reformulation or delivery technology could be substantial.
• No licensed products or ongoing clinical trials indicate lack of near-term commercial viability.
• Licensing or partnership opportunities remain slim unless technological barriers are addressed.

---

Conclusion: Investment Viability
Saralasin acetate holds limited investment appeal in its current form. Its development history signals high technical barriers and intense competition from well-established oral agents. Unless innovations emerge addressing peptide stability and delivery, it remains a niche research tool rather than a commercially viable drug candidate.

---

Key Takeaways

• Saralasin acetate is a peptide angiotensin receptor antagonist with historical research use.
• Development halted due to pharmacokinetic limitations and competitive market landscape.
• Peptide instability and delivery challenges deter mainstream therapeutic development.
• No active patents or clinical programs suggest minimal near-term commercialization chances.
• Future value may depend on breakthroughs in peptide stabilization or delivery technologies.

---

FAQs

Last updated: February 3, 2026

1. Is saralasin acetate approved for clinical use?
   No, it is not approved for human therapy; it primarily exists as a research tool.

2. Can saralasin acetate be used for any current medical condition?
   No, its use is limited to experimental settings, with no approved indications.

3. Are there any ongoing clinical trials involving saralasin?
   No recent clinical trials are publicly registered, indicating clinical development is inactive.

4. What are the main technical barriers to saralasin’s development?
   Peptide instability, poor oral bioavailability, and short half-life.

5. Could new delivery technologies revive saralasin’s prospects?
   Potentially, but significant technological breakthroughs are required, and no current efforts are evident.

---

References
[1] US Patent Office. Patent filings related to saralasin.
[2] ClinicalTrials.gov. Records of any trials involving saralasin.
[3] Scientific literature on peptide angiotensin antagonists.
[4] Market analyses of antihypertensive drugs.